PUBLICATIONS

Home PUBLICATIONS

DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, Thorne SH, Hinck AP, and Delgoffe GM, An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. J. Exp. Med. 2023 Vol. 220 No. 10 e20230053

Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, Zhang Y (2020) CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 8(1):e000131 PMID: 32098828

Rivadeneira DB, DePeaux K, Wang Y, et al. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. 2019;51

Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM (2019) Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. 51(3):548-560. PMID: 31471106

Shao L, Hou W, Scharping NE, Vendetti FP, Srivastava R, Roy CN, Menk AV, Wang Y, Chauvin JM, Karukonda P, Thorne SH, Hornung V, Zarour HM, Bakkenist CJ, Delgoffe GM, Sarkar SN (2019) IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. Cancer Immunol Res. 7(8):1258-1266. PMID: 31239318

Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, Albelda SM. (2018) Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology. 7(3): PMID: 29399394

Berkey SE, Thorne SH, Bartlett DL. (2017) Oncolytic Virotherapy and the Tumor Microenvironment. Adv Exp Med Biol. 1036:157-172 PMID: 29275471

Berkey SE, Thorne SH, Bartlett DL. (2017) Oncolytic Virotherapy and the Tumor Microenvironment. Adv Exp Med Biol. 1036:157-172 PMID: 29275471

Thorne SH (2016) Virus fuels NK cell killing of leukemia. Blood. (Epub) PMID 27231392

Thorne SH (2016) Adding STING to the tale of Oncolytic Virotherapy. Trends in Cancer 2(2):67-68 PMID: 27004260

Sampath P, Thorne SH (2015) Novel therapeutic strategies in human malignancy: Combining immunotherapy and oncolytic virotherapy. Oncolytic Virotherapy 4:75-82

Rojas J, Sampath P, Hou W, Thorne SH (2015) Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clin. Cancer Res. [Epub ahead of print] PMID: 26187615

Zeh H, Downs-Canner S, McCart J, Guo Z, Rao U, Ramalingam L, Thorne S, Jones H, Kalinski P, Wieckowski E, O’Malley M, Daneshmand M, Hu K, Bell J, Hwang T, Moon A, Breitbach C, Kirn D, Bartlett D (2014) .First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread and Anti-tumor Activity. Mol Ther.

Thorne SH. (2014). Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol. 4:155. PMID: 24987615

Hou W, Chen H, Rojas J, Sampath P, Thorne SH (2014) Oncolytic Vaccinia Virus Demonstrates Anti-angiogenic Effects Mediated by Targeting of VEGF. Int J Cancer. 2014 [Epub ahead of print] PMID: 24474587

Albelda SM, Thorne SH. (2014) Giving Oncolytic Vaccinia Virus More BiTE. Mol Ther. (1):6-8. PMID: 24384909

Sampath P, Thorne SH. (2013) Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses. Oncolytic Virotherapy. 3:1-9 PMID

Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A. (2012) High mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 2012 Jan 11 [Epub ahead of print] PMID: 22234969

Thorne SH. (2011) Next-generation oncolytic vaccinia vectors. Methods Mol Biol. 2012;797:205-15. PMID: 21948478

Li J, O’Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL. (2011) Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer. Mol Ther. Jan 25. [Epub] PMID: 21266959

Huang B, Sikorski R, Kirn DH, Thorne SH. (2010) Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 2010 Aug 26. [Epub] PMID: 20739958

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC (2010). Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. Mol Ther. 2010 Mar 16. [Epub] PMID: 20234341

Thorne SH (2009) Design and testing of novel oncolytic vaccinia strains. Methods Mol Biol. 542: 635-647

Kirn DH, Thorne SH. (2009) Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9(1): 64-71

Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH (2008) Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. April 68(7): 2071-5

Thorne SH, Hermiston T, Kirn D (2005). Oncolytic Virotherapy:  Approaches to Tumor Targeting and Enhancing Antitumor Effects. Sem Onc. Dec:32:537-548

JAMES M. BURKE, M.D.

Chief Medical Officer

Dr. James Burke is a University of California, San Francisco trained hematologist and oncologist who has led clinical development of gene therapy and oncolytic viruses for cancer for over 15 years including first in human through Phase 3 studies. Most recently, Dr Burke served as Chief Medical Officer of Sillajen (previously Jennerex) leading Phase 1-3 global development of a vaccinia virus platform for multiple cancers including HCC, RCC, and CRC.

The global Phase 3 registration trial targeting advanced HCC represents one of the largest oncolytic studies conducted to date spanning four continents including North America, Europe, Australia, and Asia. This Phase 3 study was the first oncolytic virus study conducted by a foreign biotech in China and one of only a few OV trials to ever be conducted in mainland China. Aside from Sillajen, Dr Burke led initial Phase 1-2 clinical development of Turnstone’s maraba virus prime-boost oncolytic virus program as CMO through initial studies and fund raising.

Dr Burke started his career at Cell Genesys spearheading early gene and immunotherapy studies including oncolytic adenovirus, lentivirus, AAV, and tumor vaccine programs. In addition to his biotechnology experience, Dr Burke directed studies as a clinical scientist including first in human studies in oncolytic viruses, tumor vaccines, as well as other cancer therapeutics in Phase 1-3 development.

Throughout his career he has had extensive interaction with global regulatory authorities and key academicians, led clinical development of numerous agents, built expert research teams, presented his research findings in key scientific journals and symposia, and led medical discussions and negotiations with external financing entities including venture capital and pharma.

ADINA PELUSIO

Senior Vice President of Clinical Operations

Ms. Pelusio has more than 20 years of experience in drug development. Before joining KaliVir, she served as Senior Vice President of Clinical Operations at Turnstone Biologics, where she oversaw the advancement of candidate oncolytic viruses, cancer vaccines and adoptive cell therapies into clinical trials. Prior, Ms. Pelusio spent 10 years at SillaJen, Inc. (formerly Jennerex Biotherapeutics) where she led the introduction of oncolytic viruses into 17 countries across Phase I-III clinical trials. She holds an M.S. from the University of Florida and is pursuing an M.P.H. from Harvard University T.H. Chan School of Public Health.

STEPHEN H. THORNE, Ph.D.

Chief Scientific Officer

Stephen Thorne co-founded Kalivir in 2019 and currently serves as Chief Scientific Officer. He is a leader in the field of oncolytic viral immunotherapy and previously co-founded Western Oncolytics, BioEclipse and Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials.

Stephen was a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London. Stephen has served in post doctorate roles at Surrey University, Cancer Research UK, and Stanford University and has authored more than 100 scientific publications in the field.

HELENA CHAYE, Ph.D., J.D.

Chief Executive Officer

Helena has over 23 years of experience in the biotechnology industry having held leadership positions in operations, corporate affairs, business development and IP management primarily in oncolytic virotherapy development. Most recently, Helena served as Chief Business Officer at SillaJen Biotherapeutics, Inc. where she managed all operations including corporate and business development strategies, R&D strategy and intellectual property. Prior to joining SillaJen, Helena held the positions of VP of Corporate Affairs & IP at Jennerex Biotherapeutics and the Director of Business Development at MediGene. Helena received her B.S. in Biochemistry and her Ph.D. in Genetics from the University of British Columbia and her J.D. from Dalhousie University.